Composition
- Active ingredients
- DOLUTEGRAVIR 50MG/300MG/300MG; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA217016.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Dolutegravir; Tenofovir Disoproxil Fumarate; Lamivudine
- Active substance
- dolutegravir
- Route
- Oral
- Dosage form
- Tablet
- Applicant
- Strides Pharma
- Status
- Tentative approval
- FDA approval
- 14 Sept 2023
- Application
- NDA217016-001